In similar studies conducted by Scotti et al, combining G129R-hPRL with Herceptin resulted in suppression of STAT3 and STAT5 phosphorylation and reduced HER2 expression in T47D and BT474 breast cancer cells (54). This evidence concerns the gene STAT5A and breast carcinoma.